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a b s t r a c t
A systematic approach was developed to investigate the stability of gentamicin sulfate (GS) and GS/poly
(lactic-co-glycolic acid) (PLGA) coatings on hydroxyapatite surfaces. The inﬂuence of environmental
factors (light, humidity, oxidation and heat) upon degradation of the drug in the coatings was in-
vestigated using liquid chromatography with evaporative light scattering detection and mass spectro-
metry. GS coated rods were found to be stable across the range of environments assessed, with only an
oxidizing atmosphere resulting in signiﬁcant changes to the gentamicin composition. In contrast, rods
coated with GS/PLGA were more sensitive to storage conditions with compositional changes being de-
tected after storage at 60 °C, 75% relative humidity or exposure to light. The effect of γ-irradiation on the
coated rods was also investigated and found to have no signiﬁcant effect. Finally, liquid chromatography–
mass spectrometry analysis revealed that known gentamines C1, C1a and C2 were the major degradants
formed. Forced degradation of gentamicin coatings did not produce any unexpected degradants or im-
purities.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Over the past decade, scientists have been working at the
frontier between materials science and pharmaceutics to develop
new orthopedic devices with functionalized antibacterial coatings
[1–5]. This interest has been driven by the ongoing problem of
periprosthetic joint infection in 0.3%–9% of patients following total
replacement of the hip, knee or ankle [6]. Patients with implanted
devices are particularly susceptible to infection due to compro-
mised host defense at the implant/tissue interface [1,7]. Further-
more, implant adherent bacteria typically exist as a bioﬁlm, which
protects the former from the host immune system and anti-
bacterial agents [8,9]. Treatment of such bacterial bioﬁlm usually
requires surgical removal of the implant, followed by replacement
in one or two stages depending on the nature of the infection [6].
Therefore, it becomes necessary to explore alternative procedures
for preventing implant associated infections in the ﬁrst instance.
One such method is the application of antimicrobial coatings to
the biomedical implant. Such coatings can disrupt the adhesion of
bacteria to the implant surface, and bolster the host's immune
system in the interface region between implant and tissue [1].
Gentamicin is the antibiotic most widely exploited in antibiotic
coatings of implants due to its relatively broad antibacterial
spectrum and thermal stability [1,3,4]. Other antimicrobials which
have also been used in implant coatings include cephalothin [4],
carbenicillin [4], amoxicillin [4], cefamandol [4], tobramycin [4],
vancomycin [4,10,11], chlorhexidine [12], chloroxylenol [13], silver
[14], copper [15], and zinc [16].
Gentamicin is an aminoglycoside antibiotic consisting of four
major components (C1, C1a, C2, C2a) and a minor component C2b
which are produced by fermentation ofMicromonospora purpurea or
Micromonospora echinospora (Fig. 1) [17,18]. The ratio of the in-
dividual congeners is dependent on the origin of the sample and
accepted limits to these ratios are speciﬁed in the United States and
European Pharmacopoeias [19,20]. During the fermentation process
a number of other minor impurities (e.g. sisomicin, and JI-20B) and
degradation products (2-deoxystreptamine, and garamine) can also
be formed (Fig. 1) [21]. Bulk gentamicin mixtures as an active
pharmaceutical ingredient (API) are typically characterized by high
performance liquid chromatography (HPLC) with the detection of
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the major components facilitated by UV detection of their ortho-
phthaldehyde derivatives [22,23], pulsed electrochemical detection
[24–26], charged aerosol detection [27] or evaporative light scat-
tering detection (ELSD) [24,28,29]. Liquid chromatography–mass
spectrometry (LC–MS) has also been employed to establish impurity
proﬁles of gentamicin mixtures [30–32].
A particular formulation has been developed and investigated
in previous studies [33–36], with the objective of clinical use in
cementless hip prostheses. In vitro testing of grit blasted and
porous titanium coupons coated with 1.0 mg gentamicin per cm2
and a poly(lactic-co-glycolic acid) (PLGA) overcoat has shown
them to be as efﬁcacious as a commercially available antibiotic-
loaded bone cement for preventing infection [33,34]. Subsequent
in vivo studies have demonstrated both the antibacterial efﬁcacy
of this coating formulation and that it supports the integration of
bone tissue into the implant surface through its relatively fast
in vivo dissolution [35,36]. As part of this convergent technology
development it is necessary to investigate the stability of the ac-
tive drug coating under common sterilization and storage condi-
tions used for medical implants.
The degradation of gentamicin as a pure API or in solution is
well established [37]. However, alternative degradation pathways
might be possible on interaction of gentamicin with the surface of
a medical device. Friess and Schlapp [38] have reported the short-
term stability of gentamicin loaded PLGA microparticles and col-
lagen/PLGA composites sterilized by ethylene oxide treatment as
well as β- and γ-irradiation. Ethylene oxide sterilization resulted in
chemical changes to the gentamicin drug substance, while storage
of irradiated samples at 40 °C and 75% relative humidity (RH) re-
sulted in degradation of the polymer support. To our knowledge
there have been no reported studies for the degradative behavior
of gentamicin on titanium or hydroxyapatite device surfaces.
The goal of this study was to evaluate the degradation pathways
of gentamicin coatings on hydroxyapatite implant devices under
common storage conditions. While gentamicin is known to be a heat
stable antibiotic when stored under standard conditions as an API,
incorporation on the surface of a material may lead to different
stability levels and degradation pathways. Accordingly, a range of
temperatures were studied to establish the thermal stability/lability
of gentamicin on surfaces. The impact of sterilization by γ-irradia-
tion of the drug/device combination products was also investigated.
To facilitate these studies a simple yet robust method was developed
for the extraction of the drug coating from the combination devices.
Extracts of the drug coating were analyzed by HPLC with ELSD to
determine the ratio of the major components in the gentamicin
coating. The extracts were also analyzed for common gentamicin
degradants and impurities using LC–MS. In the present study gen-
tamicin sulfate (GS) coated hydroxyapatite rods were used as a
convenient model system for larger implant devices.
2. Experimental
2.1. Reagents and chemicals
GS was obtained from Lek (Lubljana, Slovenia). HPLC grade
water, acetonitrile and methanol were from Sigma-Aldrich (St
Louis, MO, USA). Triﬂuoroacetic acid (99%) (TFA) was from Sigma-
Aldrich. Nitrogen gas (purity: 99.995%) was supplied by BOC
(Guildford, UK). GS and GS/PLGA coated hydroxyapatite rods were
obtained from DePuy Synthes (Cork, Ireland), produced via a
process equivalent to previous published work on this coating
[35,36]. The rods were received in sealed aluminum foil pouch
packaging.
2.2. Instrumentation and chromatographic conditions
2.2.1. LC–ELSD chromatographic conditions
The LC–ELSD apparatus consisted of an 1120 Compact LC system,
a 385-ELSD evaporative light scattering detector and ChemStation
B.04.03 software (all from Agilent Technologies, Santa Clara, CA,
USA) for data acquisition. Nitrogen (purity 99.995%) was used as the
evaporation gas at a ﬂow rate of 1.6 L/min. ELSD was operated with
the nebulizer and evaporator temperatures of 40 °C.
The LC–ELSD method was adapted from those previously re-
ported by Agilent Technologies [39] and Clarot et al. [28]. An
Fig. 1. Structure of gentamicin congeners as well as its common impurities and degradants.
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Atlantis T3 C18 column (150 mm4.6 mm, 5 mm, Waters, Milford,
MA, USA), maintained at 25 °C in the 1120 Compact LC column
heater, was used for chromatography. The mobile phase was an
isocratic mixture of an aqueous solution of triﬂuoroacetic acid
(0.2 mol/L, pH 1.5) and methanol in a ratio of 92:8 (v/v). The
mobile phase ﬂow rate was 1 mL/min.
All GS standard solutions were prepared in water. The injection
volume was 10 mL. GS standards were prepared at concentrations
of 0.1–1 mg/mL and used to calibrate the detector response.
2.2.2. LC–MS chromatographic conditions
The LC–MS apparatus consisted of a 2695 Separations Module,
a 2996 Photodiode Array Detector, an LCT Premier KD160 mass
spectrometer and MassLynx 4.1 software (all fromWaters, Milford,
MA, USA) for data acquisition. Chromatographic column and
conditions employed for LC–MS studies were the same as given
above for the LC–ELSD data generation.
2.2.3. 1H nuclear magnetic resonance (NMR) spectroscopy analysis
1H NMR spectra were recorded in D2O on a Bruker Avance NMR
spectrometer operating at 600 MHz at room temperature (20 °C).
2.3. Isolation of gentamicin sulfate components
Pure samples of the major components of GS were isolated
using the LC–ELSD. An initial analysis of GS performed using the
LC–ELSD method reported above with an injection volume of
50 mL, provided retention times for the C1a, C2, C2a, and C1 com-
ponents. The ELSD detector was subsequently disconnected and
fractions of the eluent were collected from the detector inlet at the
previously determined time intervals (C1a 5.0–6.0 min, C2 6.9–
7.9 min, C2a 9.0–9.9 min, C1 11.0–12.0 min). Fifteen injections of a
0.25 mg/mL GS solution were processed. Evaporation to dryness of
the pooled fractions provided samples of gentamicin C1a, C2, C2a,
and C1 in good purity, as determined by LC–ELSD, NMR spectro-
scopy and high resolution mass spectrometry (HRMS).
2.4. Chemical stability
The stability of GS coated rods under a range of storage con-
ditions was studied over 30 days. The variations of storage con-
ditions investigated are shown in Table 1.
(i) Thermal: samples were stored at a low temperature (4 °C) or
high temperature (60 °C) in sealed vessels to establish the
thermal stability of the gentamicin on the rods.
(ii) Sensitivity to oxidation: oxidizing storage conditions were si-
mulated by suspension of samples over a solution of 30% (m/
m) hydrogen peroxide, while in contrast to simulate storage in
a non-oxidizing environment samples were stored under ni-
trogen gas at 20 °C. Both were shielded from light.
(iii) Humidity: humidity variations were simulated by sample sto-
rage at low humidity (20% RH, suspension over saturated po-
tassium acetate solution) or high humidity (75% RH, suspen-
sion over saturated sodium chloride solution) in sealed con-
tainers at 20 °C [40].
(iv) Light: low light storage conditions were simulated by storage
of the samples in open foil pouches at 20 °C while high light
conditions were achieved by storage of the samples under a
ﬂuorescent light.
(v) Irradiation: GS coated rods were subjected to sterilization by
γ-irradiation (carried out by DePuy Synthes) at low (25 kGy)
and high (40 kGy) doses [41].
On completion of the storage period, the organic material was
extracted from the coated hydroxyapatite rods by immersion in a
solution of TFA/acetonitrile/water (0.3/3/97, v/v/v) [200 mL]. The
vessels were sonicated for 1 h at room temperature. The resulting
solution was ﬁltered and evaporated to dryness. Portions of the
residues (10 mg) were dissolved in water (1 mL) and analyzed by
LC–ELSD and LC–MS. LC–ELSD results were recorded as % (m/m)
based on the assumption that structurally similar gentamicin
congeners have the same ELSD response factors [42] (Table S1).
LC–MS results were recorded as peak area ratios relative to the
gentamicin C1 peak area.
As summarized in Table 1, the samples of GS coated rods were
originally received in sealed foil pouches under a protective atmo-
sphere. For the light, humidity and oxidation stability tests the pou-
ches were opened to enable exposure of the coating to the appro-
priate test conditions. Accordingly, exposure to open atmosphere in
addition to the speciﬁc stability tests was incorporated in the study.
3. Results and discussion
3.1. Analysis of bulk gentamicin sulfate
The European Pharmacopoeia deﬁnes acceptable limits for the
composition of GS (Table 2) [19]. The bulk GS used for preparing
coated devices in this study was examined using LC–ELSD to de-
termine its composition before the application of the device
coating (Fig. 2). The composition of the bulk material was also
determined separately using 1H NMR spectroscopy. The anomeric
protons of the four gentamicin constituents could be separately
assigned by resolution of the signal at 5.9 ppm. Integration of this
signal revealed the ratio of gentamicin components [43]. The LC–
Table 1.
Environments for chemical stability tests.
Environment Conditions
Low light Rods were stored in the foil pouch packaging with a small opening to allow for air penetration at 20 °C in the dark.
High light Rods were removed from the foil pouch and placed under a ﬂuorescent lamp.
Low temperature Rods were stored in the sealed foil pouch packaging and refrigerated at 4 °C.
High temperature Rods were stored in the sealed foil pouch packaging in an oven at 60 °C.
Low humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and suspended in a sealed container containing a
saturated potassium acetate solution at 20 °C (20% RH).
High humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and suspended in a sealed container containing a
saturated sodium chloride solution at 20 °C (75% RH).
Low oxidation Rods were stored in opened foil pouches, shielded from light, at 20 °C, under a nitrogen atmosphere.
High oxidation Rods were stored in opened foil pouches, shielded from light, at 20 °C, suspended over a solution of 30% hydrogen peroxide.
Low irradiation Rods in their sealed foil packaging were subjected to a standard gamma dose (25 kGy)
High irradiation Rods in their sealed foil packaging were subjected to a high gamma dose (40 kGy).
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ELSD and 1H NMR spectroscopy determinations for our GS were in
agreement, and were within the European Pharmacopoeia limits.
This also veriﬁed that the major components of GS displayed an
equivalent response in ELSD detection.
3.2. Isolation of gentamicin sulfate components
The individual gentamicin C1, C1a, C2 and C2a congeners were
isolated using HPLC to provide pure standards for use in our LC–
ELSD and LC–MS analyses (Fig. S1).
3.3. Chemical analysis of gentamicin coated hydroxyapatite devices
In order to study the gentamicin coating on medical devices it
was desirable to have a method for the extraction of the coating
into a solution. The extraction of the gentamicin coating could be
effectively achieved by sonication of the coated rods in a solution
of triﬂuoroacetic acid, acetonitrile and water in a ratio of 0.3:3:97
(v/v/v) at room temperature. Subsequent analysis of the con-
centrated extract by LC–ELSD revealed a gentamicin composition
of 41% C1, 8% C1a, 43% C2 and 8% C2a. While this composition was
marginally outside of the European Pharmacopoeia speciﬁcation
for gentamicin drug product, it was considered sufﬁciently close to
that of the bulk GS to indicate that the extraction method was
efﬁcient and non-destructive.
3.4. Stability of the gentamicin sulfate coating studied by LC–ELSD
One of the core objectives of this study was to assess the
chemical stability of gentamicin coatings on hydroxyapatite de-
vices and determine if there were environmental factors impacting
on shelf life. For the purpose of this pilot study, GS coated hy-
droxyapatite rods supplied by DePuy Synthes were subjected to a
30 day forced degradation study to determine the inﬂuence of
temperature, humidity, atmospheric oxidation and light exposure.
For these stability studies, it was important that the sealed foil
pouches in which the rods were supplied were opened for the
stability tests (other than thermal and irradiation studies) to
evaluate effect of exposure to stress factor as compared to the
packaged products. Also the hydroxyapatite rods coated with both
GS and PLGA were subjected to the same forced degradation
studies.
3.4.1. Thermal stability
Gentamicin is well noted for being a heat stable antibiotic, re-
taining its activity even after autoclaving [44,45]. It is this stability
under autoclave conditions that makes it a favored antibiotic for
use in antimicrobial coated devices [1,3,4]. In the present study,
storage of the rods in sealed pouches at temperatures of 4 °C and
60 °C had no noticeable effect on the chemical composition of the
coating consisting of just GS (Fig. 3A). When the rods coated with
both GS and PLGA were stored at 60 °C in sealed pouches, the
resulting gentamicin composition showed a small but signiﬁcant
reduction in the level of C2 (43% down to 36%) relative to the other
congeners. This result indicates that the thermal stability of GS
may be reduced in coatings containing PLGA.
3.4.2. Stability to humidity
The International Pharmacopoeia describes GS as being hy-
groscopic and susceptible to gradual degradation on exposure to a
humid atmosphere with the decomposition being faster at higher
temperatures [46]. Storage of the GS and GS/PLGA coated rods in
the opened foil packaging at a low RH of 20% resulted in no change
to the congener ratios of gentamicin in the coating. However,
storage of both types of coated rods at 75% RH resulted in small
decreases in the level of gentamicin C2 relative to the other con-
geners (Fig. 3B). The presence of PLGA in the coating had little
effect on the stability of gentamicin under high humidity. The
changes observed in this study were relatively small but it should
be noted that the high RH test was conducted at room tempera-
ture over a limited period of 30 days. A combination of high RH
and high temperature might be expected to exert more of an effect
on the gentamicin coating over longer time periods.
3.4.3. Stability to atmospheric oxidation
Oxidative processes are known to occur in the biosynthetic
interconversion of gentamicin and its several known impurities
Table 2.
Composition (m/m) of bulk gentamicin sulfate determined by LC–ELSD and 1H NMR
spectroscopy.
Methods Components (%, m/m)
C1 C1a C2 (C2þC2aþC2b)
EU Pharm. 25–45 10–30 35–55
LC–ELSD 38 11 51
1H NMR 37 14 49
Fig. 2. LC–ELSD chromatogram of gentamicin sulfate [39].
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Fig. 3. The effect of 30-day storage conditions on the composition of the GS coating determined by HPLC–ELSD. Control: control extraction, GR: GS coated rod, GPR: GS and
PLGA coated rod, LT: stored at 4 °C, HT: stored at 60 °C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored under
nitrogen atmosphere, HO: stored over 30% H2O2.
Fig. 4. The effect of 30-day storage conditions on relative level of common impurities in the GS coating determined by LC–MS. Control: control extraction, GR: GS coated rod,
GPR: GS and PLGA coated rod, LT: stored at 4 °C, HT: stored at 60 °C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored
under nitrogen atmosphere, HO: stored over 30% H2O2.
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such as JI-20B [47]. It was therefore expected that an oxidizing
atmosphere might lead to degradation of gentamicin. Also the
amino and hydroxyl functional groups in GS are reported as being
susceptible to chemical oxidation [37]. Furthermore, the glycoside
linkages of several aminoglycosides are known to be cleaved under
oxidizing conditions [48]. In the present study, no changes were
observed in the composition of GS and GS/PLGA coatings stored in
open pouches under an inert nitrogen atmosphere. Storage of the
coated rods in open pouches in an oxidizing atmosphere, over a
solution of hydrogen peroxide (30%, m/m), resulted in measurable
changes to the gentamicin composition of GS and GS/PLGA coat-
ings. Small increases in the relative level of gentamicin C2 were
observed, while gentamicin C1 was noticeably decreased from 41%
to 34% in both the GS and GS/PLGA coatings (Fig. 3C).
3.4.4. Stability to light exposure
Hydroxyapatite rods coated with either GS or GS/PLGA were
stored in the dark and under a ﬂuorescent light for 30 days in an
open atmosphere in both cases. After this period of storage, no
changes were observed in the gentamicin composition of rods
stored in the dark (Fig. 3D). The GS coated rod also appeared to be
stable to storage under the ﬂuorescent lamp with no measurable
change in the gentamicin congener ratios measured by LC–ELSD,
while the GS/PLGA coated rod did undergo changes when stored
under the lamp. Under the high light exposure conditions, the C2
level was signiﬁcantly reduced to 31% in the GS/PLGA coating. This
indicated that even though gentamicin appeared to be stable to
light, the presence of other components (such as PLGA) in anti-
microbial coatings could lead to signiﬁcant photodegradation.
3.5. Analysis of common impurities by LC–MS
The extracts obtained from the stability studies were also sub-
jected to LC–MS analysis to screen for common gentamicin im-
purities and degradants. The characteristic ions for many of these
gentamicin impurities have been previously reported [30–32]. Total
ion count chromatograms showed the presence of the ﬁve genta-
micin C components. The presence of key degradants and impurities
in the extracts were determined by ion extraction method.
Garamine fragmentation ions were detected in all samples as
multiple peaks due to fragmentation of the major gentamicin
congeners inside the mass spectrometer. However, m/z 322 peak
was also observed at 2.59 min, which was not observed with any
heavier ions, suggesting that this peak represented garamine de-
gradants formed prior to LC–MS analysis. Measurement of this
peak in the extracts revealed garamine levels of 1%–6% with the
maximum level being observed in samples stored under a highly
oxidizing atmosphere (5%–6%). No garamine was detected in the
control extract taken from a rod not subjected to forced de-
gradation studies.
The extracts were expected to contain gentamines in signiﬁcant
levels if severe degradation of the corresponding gentamicin C
components had occurred under the tested environmental con-
ditions. Gentamine C1, arising from degradation of gentamicin C1,
was observed at levels of 2%–5% in most extracts. However, there
was noticeably more gentamine C1 (19%) observed in samples
subjected to highly oxidizing conditions. Conditions of low hu-
midity also led to an increase in gentamine C1 levels (7%–9%). The
C1a and C2 gentamines showed a similar increase in levels for
samples that experienced a highly oxidizing atmosphere.
G-418, sisomicin and JI-20B are common in batches of GS and
are related to gentamicin through biotransformative processes
[47]. Sisomicin and the antibiotics JI-20B and G-418 were observed
at levels below 1% in all the samples (Fig. 4).
The storage conditions employed in this study generally had
little effect on the composition and degradation of the gentamicin
coated rods; the exception being the highly oxidizing environment
(Fig. 4). After 30 days the only major degradants observed were
gentamines arising from the cleavage of the A-ring from the B-C
gentamicin ring system. All the LC–MS peaks observed in this
study could be attributed to previously reported gentamicin im-
purities [30–32]. Thus, there was no evidence that gentamicin
underwent substantive unique degradation pathways when ap-
plied as a device coating at readily detectable levels .
3.6. Stability to γ-irradiation
γ-Irradiation is a common method for the sterilization of
medical devices and has previously been employed for gentamicin
containing PLGA composite particles [38]. Friess and Schlapp have
reported that free radicals, detected by electron spin resonance
spectroscopy, were formed in gentamicin loaded particles ster-
ilized by exposure to 28.9 kGy of γ-irradiation. These free radicals
did not persist beyond four weeks in gentamicin and had no de-
tectable effect on the 1H NMR spectrum of gentamicin. [38] In our
study, we employed 25 kGy and 40 kGy dosages of γ-irradiation to
sterilize GS and GS/PLGA coated hydroxyapatite rods. LC–ELSD and
LC–MS analysis of extracts after low and high dose γ-irradiation
did not display any signiﬁcant changes compared to extracts from
unsterilized rods (Fig. 5). These results conﬁrmed that γ-irradia-
tion is a suitable sterilization method for use with gentamicin
coated medical implants.
As stated, LC–ELSD analysis revealed that the change in com-
position of the gentamicin congeners (gentamicin C1, C1a, C2 and
C2a) was very small across the range of conditions studied. The
largest variation seen in rods stored under high humidity and
Fig. 5. (A) The effect of γ-irradiation on the GS composition (measured by HPLC–
ELSD) and (B) the relative levels of common GS impurities (measured by LC–MS).
Control: control extraction, GR: GS coated rod, GRP: GS and PLGA coated rod.
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oxidation. The proportion of gentamicin C2 changed by 5%
(Figs. 3B and 3C). A comparison of the change in composition of
the minor impurities using LC–MS revealed that the biggest
change was seen in the amounts of gentamine C1 formed after
storage (Fig. 6). Under conditions of low humidity both GS coated
rods and those coated with GS and PLGA showed a signiﬁcant
increase in levels of gentamine C1 detected. This effect was even
more pronounced when rods subjected to highly oxidizing con-
ditions were examined. In addition, an increase in the other gen-
tamine impurities (gentamines C1a and C2) was also evident.
4. Conclusions
GS and GS/PLGA coated hydroxyapatite rods were subjected to
high and low temperature, humidity, oxidation and light exposure
environments over a period of 30 days. LC–ELSD and LC–MS ana-
lyses of extracts from GS coated rods indicated that they were
stable under storage at 60 °C and also to light exposure. High
humidity had a minimal effect on the composition of GS. In con-
trast, rods coated with both GS and PLGA were more sensitive to
storage conditions with compositional changes being detected
after storage at 60 °C, 75% RH or exposure to light. Storage of both
GS and GS/PLGA coated rods in an oxidizing atmosphere resulted
in signiﬁcant changes to the gentamicin composition but no un-
expected impurities were detected by LC–MS. The major de-
gradants detected were the gentamines arising from degradation
of the corresponding gentamicin C components. Finally, the effect
of γ-irradiation on the gentamicin composition of GS and GS/PLGA
coated rods was also investigated and found to have no signiﬁcant
effect. Based on this preliminary study, investigation of long-term
storage of the GS and GS/PLGA coated rods under appropriately
controlled conditions (namely protected from light, avoiding high
temperature and exposure to air) is warranted.
In conclusion, a systematic approach has been developed to
investigate the chemical stability of drug coatings applied to
medical implant devices. This methodology was applied to the
study of hydroxyapatite rods coated with gentamicin to determine
the degradative behavior of gentamicin on a device surface.
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